226 related articles for article (PubMed ID: 30301530)
21. GNG12 regulates PD-L1 expression by activating NF-κB signaling in pancreatic ductal adenocarcinoma.
Li J; Jin C; Zou C; Qiao X; Ma P; Hu D; Li W; Jin J; Jin X; Fan P
FEBS Open Bio; 2020 Feb; 10(2):278-287. PubMed ID: 31898405
[TBL] [Abstract][Full Text] [Related]
22. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
[No Abstract] [Full Text] [Related]
23. The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer.
Xu JY; Wang WS; Zhou J; Liu CY; Shi JL; Lu PH; Ding JL
Pancreas; 2019 Aug; 48(7):904-912. PubMed ID: 31268976
[TBL] [Abstract][Full Text] [Related]
24. c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer.
Lux A; Kahlert C; Grützmann R; Pilarsky C
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284422
[TBL] [Abstract][Full Text] [Related]
25. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.
Wan C; Gong C; Zhang H; Hua L; Li X; Chen X; Chen Y; Ding X; He S; Cao W; Wang Y; Fan S; Xiao Y; Zhou G; Shen A
Cancer Lett; 2016 Apr; 373(1):67-76. PubMed ID: 26803058
[TBL] [Abstract][Full Text] [Related]
26. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma.
Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X
J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046
[TBL] [Abstract][Full Text] [Related]
27. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
Soares KC; Rucki AA; Wu AA; Olino K; Xiao Q; Chai Y; Wamwea A; Bigelow E; Lutz E; Liu L; Yao S; Anders RA; Laheru D; Wolfgang CL; Edil BH; Schulick RD; Jaffee EM; Zheng L
J Immunother; 2015 Jan; 38(1):1-11. PubMed ID: 25415283
[TBL] [Abstract][Full Text] [Related]
28. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
[TBL] [Abstract][Full Text] [Related]
29. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
31. Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prognostic factors for pancreatic cancer patient survival.
Curcio C; Rosso T; Brugiapaglia S; Guadagnin G; Giordano D; Castellino B; Satolli MA; Spadi R; Campra D; Moro F; Papotti MG; Bertero L; Cassoni P; De Angelis C; Langella S; Ferrero A; Armentano S; Bellotti G; Fenocchio E; Nuzzo A; Ciccone G; Novelli F
Clin Exp Med; 2023 Dec; 23(8):5089-5100. PubMed ID: 37910256
[TBL] [Abstract][Full Text] [Related]
32. MiR-940 promotes the proliferation and migration of gastric cancer cells through up-regulation of programmed death ligand-1 expression.
Fan Y; Che X; Hou K; Zhang M; Wen T; Qu X; Liu Y
Exp Cell Res; 2018 Dec; 373(1-2):180-187. PubMed ID: 30367831
[TBL] [Abstract][Full Text] [Related]
33. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R
Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795
[TBL] [Abstract][Full Text] [Related]
34. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway.
Pu N; Gao S; Yin H; Li JA; Wu W; Fang Y; Zhang L; Rong Y; Xu X; Wang D; Kuang T; Jin D; Yu J; Lou W
Cancer Lett; 2019 Sep; 460():42-53. PubMed ID: 31233838
[TBL] [Abstract][Full Text] [Related]
35. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance.
Deng Y; Xia X; Zhao Y; Zhao Z; Martinez C; Yin W; Yao J; Hang Q; Wu W; Zhang J; Yu Y; Xia W; Yao F; Zhao D; Sun Y; Ying H; Hung MC; Ma L
Nat Commun; 2021 Dec; 12(1):7041. PubMed ID: 34873175
[TBL] [Abstract][Full Text] [Related]
36. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
Wang J; Jia Y; Zhao S; Zhang X; Wang X; Han X; Wang Y; Ma M; Shi J; Liu L
Oncogene; 2017 Nov; 36(45):6235-6243. PubMed ID: 28714960
[TBL] [Abstract][Full Text] [Related]
37. Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells.
Lehrke HD; Graham RP; McWilliams RR; Lam-Himlin DM; Smyrk TC; Jenkins S; Dong H; Zhang L
Am J Clin Pathol; 2017 Nov; 148(5):441-449. PubMed ID: 29069274
[TBL] [Abstract][Full Text] [Related]
38. Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
Li E; Xu J; Chen Q; Zhang X; Xu X; Liang T
Immunotherapy; 2023 Feb; 15(3):135-147. PubMed ID: 36779368
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of Far Upstream Element-Binding Protein 1 (FUBP1) Promotes Tumor Proliferation and Tumorigenesis of Clear Cell Renal Cell Carcinoma.
Duan J; Bao X; Ma X; Zhang Y; Ni D; Wang H; Zhang F; Du Q; Fan Y; Chen J; Wu S; Li X; Gao Y; Zhang X
PLoS One; 2017; 12(1):e0169852. PubMed ID: 28076379
[TBL] [Abstract][Full Text] [Related]
40. Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control.
Heckl SM; Mau F; Senftleben A; Daunke T; Beckinger S; Abdullazade S; Schreiber S; Röcken C; Sebens S; Schäfer H
Med Sci (Basel); 2021 Jun; 9(3):. PubMed ID: 34202040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
